<DOC>
	<DOCNO>NCT01847287</DOCNO>
	<brief_summary>The primary aim study evaluate effect use Tysabri change brain use MRI disease progression patient relapsing-remitting Multiple Sclerosis 5 year .</brief_summary>
	<brief_title>A Longitudinal Study Brain Atrophy MS Patients Over 5 Years</brief_title>
	<detailed_description>This prospective , observational , single-blinded , longitudinal study natalizumab effect brain atrophy development disability progression multiple sclerosis patient 5 year , evaluate originally treat patient natalizumab participate prospective 1- 2-year VWMTR study . ( Zivadinov et al. , 2011b ) All subject assess 5-year follow-up clinical examination obtain 1.5T MRI examination scanner undergo upgrade change period 5 year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Participation natalizumab 1year followup study Participants age 1865 Have clinically definite MS accord Polman criterion either RR RSP disease type EDSS score ≤6.5 disease duration &lt; 30 year normal kidney function ( creatinine clearance &gt; 59 mL/min ) start therapy either natalizumab IM interferon beta1a ( IFNβ1a ) Signed informed consent Normal kidney functioning ( creatinine clearance &gt; 59 ) None exclusion criteria A clinically significant infectious illness ( e.g. , cellulitis , abscess , pneumonia , septicemia ) within 30 day prior 5year followup visit Nursing mother pregnant woman need undergo 5year followup MRI Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply study protocol Any reason , opinion Investigator , indicate subject unsuitable enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Tysabri</keyword>
	<keyword>MRI</keyword>
	<keyword>Natalizumab</keyword>
</DOC>